UA106967C2 - Протипухлинні аналоги пептидів, фармацевтична композиція, спосіб одержання сполук та проміжні сполуки - Google Patents

Протипухлинні аналоги пептидів, фармацевтична композиція, спосіб одержання сполук та проміжні сполуки

Info

Publication number
UA106967C2
UA106967C2 UAA201009034A UAA201009034A UA106967C2 UA 106967 C2 UA106967 C2 UA 106967C2 UA A201009034 A UAA201009034 A UA A201009034A UA A201009034 A UAA201009034 A UA A201009034A UA 106967 C2 UA106967 C2 UA 106967C2
Authority
UA
Ukraine
Prior art keywords
compounds
pharmaceutical compositions
peptide analogues
intermediates preparation
anticancer peptide
Prior art date
Application number
UAA201009034A
Other languages
English (en)
Russian (ru)
Inventor
Вісенте Альберто Родрігес
Гарсіа-Ібаррола Марія Гаррансо
Перес Кармен Мурсія
Санчо Франсіско Санчес
Марчанте Марія дель Кармен Куевас
Урбано Крістіна Матео
Хуарес Ісабель Дігон
Original Assignee
Фарма Мар, С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Фарма Мар, С.А. filed Critical Фарма Мар, С.А.
Priority to UAA201406894A priority Critical patent/UA119963C2/uk
Publication of UA106967C2 publication Critical patent/UA106967C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/51—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/695—Silicon compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/30—Oxygen atoms, e.g. delta-lactones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/32—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Dermatology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)

Abstract

Сполука загальної формули (І) для застосування при лікуванні ракового захворювання,де Y вибирають з групи, яка складається з -CHR- і -CHR-CR=CR-;кожний R, Rі Rнезалежно вибирають з водню і незаміщеного С-С-алкілу;кожний R, R, R, Rі Rнезалежно вибирають з водню і незаміщеного С-С-алкілу;Rвибирають з NRRі OR;А вибирають з:,W означає NR.
UAA201009034A 2007-12-20 2008-12-19 Протипухлинні аналоги пептидів, фармацевтична композиція, спосіб одержання сполук та проміжні сполуки UA106967C2 (uk)

Priority Applications (1)

Application Number Priority Date Filing Date Title
UAA201406894A UA119963C2 (uk) 2007-12-20 2008-12-19 Протипухлинні сполуки

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07123882 2007-12-20
PCT/EP2008/068049 WO2009080761A1 (en) 2007-12-20 2008-12-19 Antitumoral compounds

Publications (1)

Publication Number Publication Date
UA106967C2 true UA106967C2 (uk) 2014-11-10

Family

ID=40580474

Family Applications (3)

Application Number Title Priority Date Filing Date
UAA201009034A UA106967C2 (uk) 2007-12-20 2008-12-19 Протипухлинні аналоги пептидів, фармацевтична композиція, спосіб одержання сполук та проміжні сполуки
UAA201406894A UA119963C2 (uk) 2007-12-20 2008-12-19 Протипухлинні сполуки
UAA201009035A UA104281C2 (uk) 2007-12-20 2008-12-19 Протипухлинні аналоги пептидів, спосіб їх одержання та фармацевтична композиція на їх основі

Family Applications After (2)

Application Number Title Priority Date Filing Date
UAA201406894A UA119963C2 (uk) 2007-12-20 2008-12-19 Протипухлинні сполуки
UAA201009035A UA104281C2 (uk) 2007-12-20 2008-12-19 Протипухлинні аналоги пептидів, спосіб їх одержання та фармацевтична композиція на їх основі

Country Status (26)

Country Link
US (4) US8710264B2 (uk)
EP (3) EP2231633B1 (uk)
JP (3) JP5727228B2 (uk)
KR (3) KR101639772B1 (uk)
CN (4) CN101903367B (uk)
AT (1) ATE549313T1 (uk)
AU (2) AU2008341670B2 (uk)
BR (2) BRPI0821116B8 (uk)
CA (2) CA2710087C (uk)
CY (1) CY1117245T1 (uk)
DK (2) DK2231633T3 (uk)
ES (3) ES2578606T3 (uk)
HR (2) HRP20120464T1 (uk)
IL (3) IL206396A (uk)
MX (2) MX2010006795A (uk)
MY (3) MY155342A (uk)
NZ (3) NZ586012A (uk)
PL (2) PL2231590T3 (uk)
PT (2) PT2231590E (uk)
RS (2) RS52343B (uk)
RU (3) RU2489429C2 (uk)
SG (2) SG170778A1 (uk)
SI (2) SI2231633T1 (uk)
UA (3) UA106967C2 (uk)
WO (2) WO2009080769A1 (uk)
ZA (3) ZA201004017B (uk)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0821116B8 (pt) 2007-12-20 2021-05-25 Pharma Mar Sa composto, composição farmacêutica que o contem, uso deste e processo para a preparação do mesmo
US9856196B2 (en) 2012-01-05 2018-01-02 Kao Corporation Agent for reduction of sensory irritation
EA029361B1 (ru) 2013-04-16 2018-03-30 Идорсиа Фармасьютиклз Лтд Антибактериальные биароматические производные
GB201309807D0 (en) * 2013-05-31 2013-07-17 Pharma Mar Sau Antibody drug conjugates
CN108467378A (zh) * 2017-02-23 2018-08-31 复旦大学 一种二氢吡喃酮类化合物及其制备方法和用途
US11332480B2 (en) 2017-04-27 2022-05-17 Pharma Mar, S.A. Antitumoral compounds

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5142056A (en) * 1989-05-23 1992-08-25 Abbott Laboratories Retroviral protease inhibiting compounds
US4855086A (en) * 1982-10-15 1989-08-08 Burroughs Wellcome Co. Novel pesticides, preparation and use
JPS61109717A (ja) * 1984-11-02 1986-05-28 Teruhiko Beppu 抗腫瘍剤
CA2098702A1 (en) * 1990-12-28 1992-06-29 James C. Powers Peptide ketoamides, ketoacids, and ketoesters
JPH0539283A (ja) * 1991-01-31 1993-02-19 Suntory Ltd 新規物質Ｓ−５９９１７ａ及びその製造方法
ZA938019B (en) 1992-11-13 1995-04-28 Upjohn Co Pyran-2-ones and 5,6-dihydropyran-2-ones useful for treating HIV and other retroviruses
US5523456A (en) * 1994-09-29 1996-06-04 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5681847A (en) * 1995-12-05 1997-10-28 Harbor Branch Oceanographic Institution, Inc. Methods of using discodermolide compounds
US5834506A (en) 1996-11-01 1998-11-10 Warner-Lambert Company Dihydropyrones with improved antiviral activity
US5840974A (en) * 1996-12-04 1998-11-24 Britisch Biotech Pharmaceuticals, Ltd. Metalloproteinase inhibitors
US6380400B1 (en) 1998-09-11 2002-04-30 Victor Fedij Methods of making dihydropyrone HIV protease inhibitors
NZ510013A (en) 1998-09-11 2003-11-28 Warner Lambert Co Dihydropyrones with selected heterocycles replacing the phenyls bearing polar substituents used as HIV protease inhibitors
WO2001074355A1 (en) * 2000-04-04 2001-10-11 Novartis Ag Method for treating cells resistant to antineoplastic agents
NZ550185A (en) * 2002-03-04 2008-10-31 Merck Hdac Res Llc Methods of inducing terminal differentiation Methods of inducing terminal differentiation
CN1856486A (zh) * 2003-07-25 2006-11-01 诺瓦提斯公司 取代的内酰胺和它们作为抗癌剂的用途
US7446196B2 (en) 2004-06-03 2008-11-04 Kosan Biosciences, Incorporated Leptomycin compounds
RU2006142690A (ru) * 2004-06-03 2008-06-10 Козан Байосайенсиз Инкорпорейтед (Us) Соединения лептомицина
WO2007014423A1 (en) * 2005-08-02 2007-02-08 Medvet Science Pty, Ltd. Exercise apparatus
ATE522514T1 (de) 2006-06-16 2011-09-15 Pharma Mar Sa Dihydropyran-2-onverbindungen mit antitumorwirkung
BRPI0821116B8 (pt) 2007-12-20 2021-05-25 Pharma Mar Sa composto, composição farmacêutica que o contem, uso deste e processo para a preparação do mesmo

Also Published As

Publication number Publication date
SI2231590T1 (sl) 2012-10-30
JP2011506575A (ja) 2011-03-03
EP2231633B1 (en) 2013-10-30
NZ597526A (en) 2012-06-29
ATE549313T1 (de) 2012-03-15
HRP20140015T1 (hr) 2014-02-14
CA2710087A1 (en) 2009-07-02
NZ586012A (en) 2011-11-25
US20100280108A1 (en) 2010-11-04
UA119963C2 (uk) 2019-09-10
CN101903337A (zh) 2010-12-01
EP2231633A1 (en) 2010-09-29
CN102190643A (zh) 2011-09-21
US20150342972A1 (en) 2015-12-03
EP2231590B1 (en) 2012-03-14
ZA201004018B (en) 2011-12-28
US20150344454A1 (en) 2015-12-03
CA2710087C (en) 2015-06-02
IL229594A0 (en) 2014-01-30
IL206396A (en) 2014-05-28
US20110034549A1 (en) 2011-02-10
ES2578606T3 (es) 2016-07-28
DK2231633T3 (da) 2014-01-20
PT2231633E (pt) 2014-01-20
WO2009080769A1 (en) 2009-07-02
JP5727228B2 (ja) 2015-06-03
IL206397A (en) 2014-01-30
US20120041063A2 (en) 2012-02-16
RU2489429C2 (ru) 2013-08-10
KR101579553B1 (ko) 2015-12-22
AU2008341671A1 (en) 2009-07-02
RU2013112003A (ru) 2014-08-20
JP5529038B2 (ja) 2014-06-25
DK2231590T3 (da) 2012-07-09
HK1147990A1 (en) 2011-08-26
US9827257B2 (en) 2017-11-28
CA2715203A1 (en) 2009-07-02
KR101639772B1 (ko) 2016-07-15
US9187445B2 (en) 2015-11-17
JP2014133752A (ja) 2014-07-24
IL206397A0 (en) 2010-12-30
KR20100125226A (ko) 2010-11-30
RU2528393C1 (ru) 2014-09-20
IL229594A (en) 2016-02-29
HK1180678A1 (en) 2013-10-25
AU2008341670A1 (en) 2009-07-02
AU2008341670B2 (en) 2012-04-19
CN101903367A (zh) 2010-12-01
KR20100100979A (ko) 2010-09-15
SG170778A1 (en) 2011-05-30
BRPI0821114B1 (pt) 2021-09-08
PT2231590E (pt) 2012-06-25
SI2231633T1 (sl) 2014-02-28
BRPI0821114B8 (pt) 2021-11-09
MX2010006795A (es) 2010-10-26
BRPI0821116B1 (pt) 2020-02-18
EP2231590B9 (en) 2012-08-15
CN102174058A (zh) 2011-09-07
MY164533A (en) 2017-12-29
CA2715203C (en) 2015-09-08
JP2011506578A (ja) 2011-03-03
ZA201106371B (en) 2013-05-29
EP2597091A1 (en) 2013-05-29
BRPI0821116A2 (pt) 2015-08-11
BRPI0821114A2 (pt) 2015-06-16
MX2010006796A (es) 2010-10-26
BRPI0821116B8 (pt) 2021-05-25
KR101541436B1 (ko) 2015-08-03
JP5860088B2 (ja) 2016-02-16
RU2493147C2 (ru) 2013-09-20
MY148651A (en) 2013-05-15
PL2231590T3 (pl) 2012-09-28
HRP20120464T1 (hr) 2012-07-31
ES2442140T3 (es) 2014-02-25
KR20150076265A (ko) 2015-07-06
US9750759B2 (en) 2017-09-05
RS53140B (sr) 2014-06-30
SG170779A1 (en) 2011-05-30
CN101903367B (zh) 2015-08-05
RU2010130180A (ru) 2012-01-27
PL2231633T3 (pl) 2014-03-31
CN101903337B (zh) 2013-12-18
AU2008341671B2 (en) 2012-07-26
ZA201004017B (en) 2011-12-28
EP2231590A1 (en) 2010-09-29
RS52343B (sr) 2012-12-31
UA104281C2 (uk) 2014-01-27
US8710264B2 (en) 2014-04-29
WO2009080761A1 (en) 2009-07-02
HK1147998A1 (en) 2011-08-26
CN102190643B (zh) 2015-02-25
RU2010130253A (ru) 2012-01-27
MY155342A (en) 2015-10-15
EP2597091B1 (en) 2016-04-20
CY1117245T1 (el) 2017-04-05
RU2528393C9 (ru) 2015-01-10
NZ586013A (en) 2012-02-24
ES2384420T3 (es) 2012-07-04
IL206396A0 (en) 2010-12-30

Similar Documents

Publication Publication Date Title
TW200745084A (en) Novel compounds
MX2009006742A (es) Inhibidores acilaminopirazoles como fgfr.
TW200716606A (en) Chemical compounds
TW200800963A (en) Chemical compounds
SI1853602T1 (sl) Kemične spojine
SI1853588T1 (sl) Kemične spojine
TW200616995A (en) Novel compounds
TW200621737A (en) 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof
TW200800999A (en) Novel compounds
GEP20146146B (en) Pyrrolopyrimidine compounds as inhibitors of cdk4/6
UA93425C2 (uk) Похідні гідантоїну, що застосовуються як mmp інгібітори
GEP20125469B (en) Inhibitors of akt activity
MX2010002419A (es) (ciclopropilfenil) feniloxamidas, metodo para su produccion y uso como un medicamento.
TW200833663A (en) Therapeutic agents
MX2007002398A (es) Nuevas composiciones farmaceuticas para el tratamiento de cancer.
UA102543C2 (uk) Феніл- та бензодіоксинілзаміщені похідні імідазолів
IN2012DN03182A (uk)
MX2010009022A (es) Derivados 16 alfa, 17 alfa-acetal glucocorticoesteroideos y su uso.
MX2011008195A (es) Derivados de indol como agentes anticancer.
TW200738659A (en) Novel compounds
WO2009015368A3 (en) Multikinase inhibitors for use in the treatment of cancer
PL1758852T3 (pl) Podstawione związki cyklopentenu
TW200639156A (en) New compounds
MY147770A (en) Novel compounds
TW200745122A (en) New compounds I